VIVUS extends return date of STENDRA commercial rights
VIVUS and Auxilium announced an extension of the termination date of the license agreement between Auxilium and VIVUS for STENDRA® (avanafil) U.S. and Canadian commercial rights through Sept. 30, 2016. STENDRA® (avanafil) is approved in the U.S. by the FDA for treatment of erectile dysfunction. August 29, 2016